Neurocrine Biosciences (NBIX) Net Cash Flow Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -22.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.40% |
| Mar 31, 2026 | -41.05% |
| Dec 31, 2025 | 92.82% |
| Sep 30, 2025 | 16.04% |
| Jun 30, 2025 | 38.42% |
| Mar 31, 2025 | 16.16% |
| Dec 31, 2024 | -80.69% |
| Sep 30, 2024 | 78.37% |
| Jun 30, 2024 | -165.25% |
| Mar 31, 2024 | -4.27% |
| Dec 31, 2023 | 43.53% |
| Sep 30, 2023 | 135.66% |
| Jun 30, 2023 | -37.16% |
| Mar 31, 2023 | -60.44% |
| Dec 31, 2022 | 42.99% |
| Sep 30, 2022 | 24.57% |
| Jun 30, 2022 | -52.80% |
| Mar 31, 2022 | 1.42% |
| Dec 31, 2021 | 36.62% |
| Sep 30, 2021 | -57.96% |